Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshimitsu Fujii

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Journal of Gastroenterology and Hepatology|May 15, 2025
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective StudyTadakazu Hisamatsu, Taku Kobayashi, Satoshi Motoya, et al.
Intestinal Research|January 16, 2025
Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Gastro Hep Advances|November 24, 2025
Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North StudyHiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 StudiesRemo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Inflammatory Intestinal Diseases|July 16, 2025
Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative AnalysisShintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, et al.
Inflammatory Intestinal Diseases|May 22, 2019
Risk Factors for Mortality in <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Inflammatory Bowel DiseaseAtsushi Yoshida, Noriko Kamata, Akihiro Yamada, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2024
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in JapanShintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, et al.
BMJ Open Gastroenterology|November 14, 2023
COVID-19 severity is associated with the risk of gastrointestinal bleedingShuji Hibiya, Takashi Fujii, Toshimitsu Fujii, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2024
Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in JapanShintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, et al.
Journal of Gastroenterology and Hepatology|May 3, 2019
Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurineShintaro Akiyama, Katsuyoshi Matsuoka, Kyoko Fukuda, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Journal of Gastroenterology and Hepatology|May 15, 2025
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective StudyTadakazu Hisamatsu, Taku Kobayashi, Satoshi Motoya, et al.
Intestinal Research|January 16, 2025
Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world studyTaku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, et al.
Gastro Hep Advances|November 24, 2025
Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North StudyHiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 StudiesRemo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Inflammatory Intestinal Diseases|July 16, 2025
Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative AnalysisShintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, et al.
Inflammatory Intestinal Diseases|May 22, 2019
Risk Factors for Mortality in <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Inflammatory Bowel DiseaseAtsushi Yoshida, Noriko Kamata, Akihiro Yamada, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2024
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in JapanShintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, et al.
BMJ Open Gastroenterology|November 14, 2023
COVID-19 severity is associated with the risk of gastrointestinal bleedingShuji Hibiya, Takashi Fujii, Toshimitsu Fujii, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2024
Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in JapanShintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, et al.
Journal of Gastroenterology and Hepatology|May 3, 2019
Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurineShintaro Akiyama, Katsuyoshi Matsuoka, Kyoko Fukuda, et al.
Pageof 9